Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting

Internal Medicine Journal

Volumn 39, Issue 8, 2009, Pages 519-526

  Prajogo, J ^a   Neil, A ^b   Duke, J ^c   Zhang, H ^f   Stokes, B ^d   Rowlings, P ^d,e,g  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Consultant Health Economist ^*  (United States)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e Hunter Area Pathology Service   (United States)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

Bone marrow transplant; Cost effectiveness; Incremental cost effectiveness ratio; Non Hodgkin lymphoma; Peripheral blood stem cell transplant

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; COHORT STUDIES; COST-BENEFIT ANALYSIS; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MODELS, ECONOMIC; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69549129501     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01795.x     Document Type: Article

References (23)

1. Australian Institute of Health and Welfare. Cancer data online, Excel tables: major cancers, age-standardized incidence rates, 1996-2004 [cited 9 Aug 2004]; Available from URL: http://www.aihw.gov.au/cancer/data/excel-tables/ index.cfm
2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive Non-Hodgkin's lymphoma. N Engl J Med 1995 333 : 1540 1545.
3. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004 104 : 626 633. (Pubitemid 38970553)
4. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, Huijgens PC, van Imhoff GW, Löwenberg B et al. Cost of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in the Netherlands. Bone Marrow Transplant 1995 15 : 605 610.
5. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Lowenberg B, Rutten FFH. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate and high grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995 16 : 463 470.
6. Messori A, Bonistalli L, Constantini M, Alterine R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997 19 : 275 281.
7. Herrman RP, Leather M, Leather HL, Leen K. Clinical care for patients receiving autologous hematopoietic stem cell transplantation in the home setting. Oncol Nurs Forum 1998 25 : 1427 1432.
8. Commonwealth Department of Health and Aged Care 2001. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Canberra : AusInfo Effective from 1st August 2001.
9. Caswell A, Reckmann M, Alexander W, Tan B, eds. MIMS Australia (3). St Leonards, Sydney : MediMedia Australia Pty 2001.
10. NSW Health Department. Health Services Act 1997 Scale of Fees for Hospital and Other Health Services, Circular No. 2001/77; 28 July 2000.
11. Commonwealth Department of Health and Aged Care. Medicare Benefits Schedule Book 1. Canberra : DHAC; 2000 Nov.
12. Petitti DB. Meta-analysis, Decision Analysis and Cost-Effective Analysis: Methods for Quantitative Synthesis in Medicine. 2nd edition. Oxford : Oxford University Press 2000 182 201.
13. Wolfram Research Inc. Mathematica V.5 [computer program]. 100 Trade Center Drive, Champain IL USA.
14. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. Bone Marrow Transplant 1989 4 : 445 448.
15. Loberiza F. Report on state of the art in blood and marrow transplantation. IBMTR/ABMTR 2004 22 : 5 9.
16. Reserve Bank of Australia. Bulletin Statistical Table: F11 Exchange Rates [homepage on the Internet]. Reserve Bank of Australia [cited 26 Aug 2004]; Available from URL: http://www.rba.gov.au/statistics/Bulletin/index.html
17. Australian Institute of Health and Welfare 2002, Health Expenditure Australia 2000-01. Health and Welfare Expenditure 8 Series, Canberra : AIHW 2002 Sept No.: 14.
18. WHO 2000. Bulletin of the World Health Organization [homepage on the Internet] cited 2001 Aug 27]; Available from URL: http://www.who.int/bulletin/ news/2000/vol.78no.2/cost-effectiveness.htm/
19. Australian Bureau of Statistics 2003, Australian System of National Accounts. Canberra : ABS 1999 Catalogue No.: 5204.0.
20. Adu A. Applying Health Economics to the Australian Pharmaceutical Benefits Scheme Listing Process. Proceedings of the 21st Australian Conference of Health Economists, Canberra, 1995 July Sydney : ASHSA, 2000 103 110.
21. Sampson FC, Beard SM, Scott F, Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br J Haematol 2001 113 : 1015 1019.
22. Ouwens JP, Van Enckevort PJ, TenVergert EM, Bonsel GJ, van der Bij W, Haagsma EB et al. The cost effectiveness of lung transplantation compared with that of heat and liver transplantation in the Netherlands. Transpl Int 2003 16 : 123 127.
23. Winkelmayer WC, Weonstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluation: the special case of end-stage renal disease treatment. Med Decis Making 2002 22 : 417 430.